Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Bought by CX Institutional

CX Institutional lifted its stake in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 1.5% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,873 shares of the medical equipment provider’s stock after purchasing an additional 28 shares during the period. CX Institutional’s holdings in Intuitive Surgical were worth $920,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Creekmur Asset Management LLC raised its stake in Intuitive Surgical by 200.0% during the first quarter. Creekmur Asset Management LLC now owns 63 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 42 shares during the period. Ridgewood Investments LLC purchased a new stake in shares of Intuitive Surgical during the 2nd quarter valued at approximately $26,000. Delos Wealth Advisors LLC lifted its holdings in Intuitive Surgical by 380.0% in the first quarter. Delos Wealth Advisors LLC now owns 72 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 57 shares during the last quarter. LRI Investments LLC purchased a new position in Intuitive Surgical in the first quarter worth approximately $30,000. Finally, LGT Financial Advisors LLC increased its stake in Intuitive Surgical by 415.4% during the second quarter. LGT Financial Advisors LLC now owns 67 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 54 shares during the last quarter. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Truist Financial upped their price target on Intuitive Surgical from $520.00 to $570.00 and gave the company a “buy” rating in a research note on Monday. Barclays increased their target price on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an “overweight” rating in a research note on Thursday, July 18th. JPMorgan Chase & Co. boosted their price target on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an “overweight” rating in a research note on Friday, October 11th. Royal Bank of Canada increased their price objective on shares of Intuitive Surgical from $515.00 to $525.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 8th. Finally, Raymond James boosted their target price on Intuitive Surgical from $500.00 to $540.00 and gave the company an “outperform” rating in a research report on Monday. Six equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $474.16.

Intuitive Surgical Price Performance

Intuitive Surgical stock opened at $476.59 on Thursday. The stock has a market cap of $169.05 billion, a PE ratio of 86.03, a P/E/G ratio of 5.40 and a beta of 1.39. The stock’s fifty day moving average is $482.49 and its two-hundred day moving average is $436.65. Intuitive Surgical, Inc. has a 1-year low of $254.85 and a 1-year high of $496.48.

Intuitive Surgical (NASDAQ:ISRG) last posted its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.24. The firm had revenue of $2.01 billion during the quarter, compared to analysts’ expectations of $1.97 billion. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The firm’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.18 earnings per share. On average, research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current fiscal year.

Insider Activity

In other Intuitive Surgical news, EVP Robert Desantis sold 1,413 shares of the company’s stock in a transaction on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the transaction, the executive vice president now owns 5,506 shares in the company, valued at $2,414,931.60. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Intuitive Surgical news, Director Amal M. Johnson sold 2,943 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $443.30, for a total value of $1,304,631.90. Following the completion of the sale, the director now owns 12,275 shares in the company, valued at approximately $5,441,507.50. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Robert Desantis sold 1,413 shares of the stock in a transaction that occurred on Friday, July 26th. The shares were sold at an average price of $438.60, for a total value of $619,741.80. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company’s stock, valued at $2,414,931.60. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 53,120 shares of company stock worth $25,528,753. Corporate insiders own 0.90% of the company’s stock.

About Intuitive Surgical

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.